Developer docs
API playgroundTry for free, no card

Search company profiles

KRKA Pharma

Full company profile

uuid00es435

Namestring
KRKA Pharma
Legal namestring
KRKA Pharma Private Limited
Company typeenum
Private
Founded yearint
2024
Descriptiontext

KRKA Pharma is a joint venture established in 2024 between Slovenia-based Krka Group, a €1.9 billion+ generic and branded-generic pharmaceutical manufacturer with 70+ years of operating history and 18 billion+ tablets/capsules produced annually, and India-based Laurus Labs, a vertically integrated pharmaceutical company with ₹6,041 crore in revenue, 6,972 employees, and 2,586 R&D personnel. The company is headquartered in Hyderabad, India, and is purpose-built to develop and manufacture generic pharmaceutical products for the Indian market and global export, leveraging Krka's formulation, regulatory, and distribution expertise alongside Laurus's API synthesis and large-scale manufacturing capability.

The company's core product strategy centers on generic pharmaceuticals — small-molecule oral solids and related dosage forms — developed and produced at greenfield facilities currently under construction in Genome Valley, Hyderabad. Technology and platform components are inherited rather than invented: Krka contributes its formulation know-how, regulatory dossiers, and USFDA/EMA/WHO compliance track record, while Laurus contributes API process IP and manufacturing scale. The technology stack is conventional pharmaceutical manufacturing rather than a novel platform.

The business model is standard generic-pharma economics: develop and manufacture off-patent molecules, sell into regulated and semi-regulated markets via distribution channels inherited from Krka (which operates in 70+ markets) and Laurus. The company holds ISO 27001 certification as an early compliance signal. Revenue mechanics — pricing model, contract structures, customer segments — are not yet disclosed because the company is pre-commercial, with no products launched and no named customers at the JV level. The single named director is Boštjan Perše.

Short descriptiontext

KRKA Pharma is a 2024 Hyderabad-based joint venture between Krka Group (Slovenia) and Laurus Labs (India) developing and manufacturing generic pharmaceuticals for India and global export markets via greenfield facilities in Genome Valley.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical manufacturing, active pharmaceutical ingredients, drug formulation development, pharmaceutical joint venture
Industry2 codes
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

KRKA Pharma develops and manufactures generic pharmaceutical products for India and global markets. The company is a 2024 joint venture between Krka Group (Slovenia) and Laurus Labs (India), currently constructing manufacturing and R&D facilities in Genome Valley, Hyderabad. Its core offering focuses on quality generic medicines, with capabilities inherited from parent companies spanning formulation development, API manufacturing, CDMO services, and large-scale production of tablets and capsules.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 18 billion+ tablets and capsules produced annually by parent company Krka Group
Product overview1 text field

KRKA Pharma Pvt. Ltd. is a joint venture pharmaceutical company established in 2024 by Krka, d. d., Novo mesto, Slovenia and Laurus Labs Ltd., India. The company is constructing manufacturing and R&D facilities in Genome Valley, Hyderabad, with a vision to develop and manufacture pharmaceutical products for India and global markets. The company focuses on generic pharmaceutical products, inheriting quality standards and product development capabilities from its parent companies, Krka Group and Laurus Labs.

Product and service1 record
1Generic pharmaceutical products
CategoryGeneric Pharmaceuticals
Description

KRKA Pharma's core offering comprises generic pharmaceutical finished dosage forms developed and manufactured for healthcare providers and pharmaceutical markets in India and globally. The product portfolio inherits formulation development and quality standards from parent company Krka Group, which produces 18 billion+ tablets and capsules annually.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Krka Group is a Europe-based generic pharmaceutical corporation with 70 years of experience, generating €1.9 billion+ annually in product and service sales. They contribute top-end quality products, innovative solutions, and extensive production, registration, and marketing-and-sales network to the joint venture.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Laurus Labs is a research-driven pharmaceutical and biotechnology company founded in 2005, generating ₹6,041 crore in FY2023 revenue. They bring CDMO services, global regulatory expertise (USFDA, WHO, EMA, etc.), and API leadership in anti-retroviral, oncology, cardiovascular, and gastro therapeutics to the joint venture.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

India-headquartered generic pharmaceutical company with global manufacturing footprint across formulations and APIs. Directly comparable as a generic finished-dose manufacturer serving India, US, and other regulated markets.

2Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India's largest pharmaceutical company and a dominant generic drug manufacturer with extensive domestic and global operations. Directly comparable as a finished-dose generic manufacturer targeting both Indian and international markets, though far larger and more diversified.

TypeDirect peer
Description

Parent company of KRKA Pharma and itself an Indian API + CDMO player with global leadership in select APIs (anti-retroviral, oncology, cardiovascular, gastro). Closely comparable given KRKA Pharma inherits Laurus Labs' CDMO, regulatory, and API expertise for finished-dose development.

4Sandoz (Novartis)
TypeBroad incumbent
Description

Global generic and biosimilar pharmaceutical company spun out of Novartis with strong European heritage similar to Krka's positioning. Comparable as a high-quality European-headquartered generics manufacturer with global ambitions and emerging market reach.

TypeBroad incumbent
Description

One of India's leading generic pharmaceutical manufacturers with a strong presence in respiratory, anti-retroviral, and chronic therapies. Comparable as a finished-dose generic manufacturer serving India and emerging markets, with overlap in Laurus Labs' therapeutic focus areas.

TypeBroad incumbent
Description

Vertically integrated Indian generic manufacturer with strong API-to-formulation integration, similar in strategic positioning to what KRKA Pharma aims to build through its Laurus Labs parentage. Compares closely as a generics manufacturer with significant US and European market exposure.

TypeBroad incumbent
Description

Major India-based generic pharmaceutical company with strong API and finished-dose capabilities across global regulated markets. Directly comparable business model (generic formulations for India + global), though with a far larger commercial footprint and product portfolio.

TypeBroad incumbent
Description

Indian pharmaceutical company with end-to-end capabilities from APIs to finished formulations, including biosimilars. Comparable as a domestic Indian generic manufacturer with global market presence and integrated value chain.

TypeDirect peer
Description

Parent company of KRKA Pharma and one of Europe's largest generic pharmaceutical companies with €1.9B+ revenue and 18B+ tablets/capsules produced annually. Directly comparable business model (small-molecule generics for global markets) and shares product-development and manufacturing DNA with KRKA Pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KRKA Pharma

Generic Pharmaceuticalskrkapharmaindia.com

KRKA Pharma is a 2024 Hyderabad-based joint venture between Krka Group (Slovenia) and Laurus Labs (India) developing and manufacturing generic pharmaceuticals for India and global export markets via greenfield facilities in Genome Valley.

What KRKA Pharma does

KRKA Pharma is a joint venture established in 2024 between Slovenia-based Krka Group, a €1.9 billion+ generic and branded-generic pharmaceutical manufacturer with 70+ years of operating history and 18 billion+ tablets/capsules produced annually, and India-based Laurus Labs, a vertically integrated pharmaceutical company with ₹6,041 crore in revenue, 6,972 employees, and 2,586 R&D personnel. The company is headquartered in Hyderabad, India, and is purpose-built to develop and manufacture generic pharmaceutical products for the Indian market and global export, leveraging Krka's formulation, regulatory, and distribution expertise alongside Laurus's API synthesis and large-scale manufacturing capability.

The company's core product strategy centers on generic pharmaceuticals — small-molecule oral solids and related dosage forms — developed and produced at greenfield facilities currently under construction in Genome Valley, Hyderabad. Technology and platform components are inherited rather than invented: Krka contributes its formulation know-how, regulatory dossiers, and USFDA/EMA/WHO compliance track record, while Laurus contributes API process IP and manufacturing scale. The technology stack is conventional pharmaceutical manufacturing rather than a novel platform.

The business model is standard generic-pharma economics: develop and manufacture off-patent molecules, sell into regulated and semi-regulated markets via distribution channels inherited from Krka (which operates in 70+ markets) and Laurus. The company holds ISO 27001 certification as an early compliance signal. Revenue mechanics — pricing model, contract structures, customer segments — are not yet disclosed because the company is pre-commercial, with no products launched and no named customers at the JV level. The single named director is Boštjan Perše.

KRKA Pharma firmographics

Firmographics
Name
KRKA Pharma
Legal name
KRKA Pharma Private Limited
Website
https://krkapharmaindia.com
Company type
Private
Founded year
2024
Operating status
Operating
Short description
KRKA Pharma is a 2024 Hyderabad-based joint venture between Krka Group (Slovenia) and Laurus Labs (India) developing and manufacturing generic pharmaceuticals for India and global export markets via greenfield facilities in Genome Valley.
Ownership category
akta.pro rank

KRKA Pharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • Drug formulation development
  • Pharmaceutical joint venture

Where KRKA Pharma is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices1 record

Markets served

KRKA Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

KRKA Pharma product offering

Product offering

Core offering

KRKA Pharma develops and manufactures generic pharmaceutical products for India and global markets. The company is a 2024 joint venture between Krka Group (Slovenia) and Laurus Labs (India), currently constructing manufacturing and R&D facilities in Genome Valley, Hyderabad. Its core offering focuses on quality generic medicines, with capabilities inherited from parent companies spanning formulation development, API manufacturing, CDMO services, and large-scale production of tablets and capsules.

Product overview

KRKA Pharma Pvt. Ltd. is a joint venture pharmaceutical company established in 2024 by Krka, d. d., Novo mesto, Slovenia and Laurus Labs Ltd., India. The company is constructing manufacturing and R&D facilities in Genome Valley, Hyderabad, with a vision to develop and manufacture pharmaceutical products for India and global markets. The company focuses on generic pharmaceutical products, inheriting quality standards and product development capabilities from its parent companies, Krka Group and Laurus Labs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic pharmaceutical products KRKA Pharma's core offering comprises generic pharmaceutical finished dosage forms developed and manufactured for healthcare providers and pharmaceutical markets in India and globally. The product portfolio inherits formulation development and quality standards from parent company Krka Group, which produces 18 billion+ tablets and capsules annually.

Quantifiable outcome

  • 18 billion+ tablets and capsules produced annually by parent company Krka Group

Companies that use KRKA Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

KRKA Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

KRKA Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Krka, d. d., Novo mesto, SloveniacoreStrategic or Co-development Partner · 1 January 2024Krka Group is a Europe-based generic pharmaceutical corporation with 70 years of experience, generating €1.9 billion+ annually in product and service sales. They contribute top-end quality products, innovative solutions, and extensive production, registration, and marketing-and-sales network to the joint venture.
  • Laurus Labs Ltd., IndiacoreStrategic or Co-development Partner · 1 January 2024Laurus Labs is a research-driven pharmaceutical and biotechnology company founded in 2005, generating ₹6,041 crore in FY2023 revenue. They bring CDMO services, global regulatory expertise (USFDA, WHO, EMA, etc.), and API leadership in anti-retroviral, oncology, cardiovascular, and gastro therapeutics to the joint venture.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

KRKA Pharma competitors and assessment

Company assessment

Broad incumbents

  • Lupin Limited: India-headquartered generic pharmaceutical company with global manufacturing footprint across formulations and APIs. Directly comparable as a generic finished-dose manufacturer serving India, US, and other regulated markets.
  • Sun Pharmaceutical Industries: India's largest pharmaceutical company and a dominant generic drug manufacturer with extensive domestic and global operations. Directly comparable as a finished-dose generic manufacturer targeting both Indian and international markets, though far larger and more diversified.
  • Sandoz (Novartis): Global generic and biosimilar pharmaceutical company spun out of Novartis with strong European heritage similar to Krka's positioning. Comparable as a high-quality European-headquartered generics manufacturer with global ambitions and emerging market reach.
  • Cipla: One of India's leading generic pharmaceutical manufacturers with a strong presence in respiratory, anti-retroviral, and chronic therapies. Comparable as a finished-dose generic manufacturer serving India and emerging markets, with overlap in Laurus Labs' therapeutic focus areas.
  • Aurobindo Pharma: Vertically integrated Indian generic manufacturer with strong API-to-formulation integration, similar in strategic positioning to what KRKA Pharma aims to build through its Laurus Labs parentage. Compares closely as a generics manufacturer with significant US and European market exposure.
  • Dr. Reddy's Laboratories: Major India-based generic pharmaceutical company with strong API and finished-dose capabilities across global regulated markets. Directly comparable business model (generic formulations for India + global), though with a far larger commercial footprint and product portfolio.
  • Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical company with end-to-end capabilities from APIs to finished formulations, including biosimilars. Comparable as a domestic Indian generic manufacturer with global market presence and integrated value chain.

Direct peers

  • Laurus Labs: Parent company of KRKA Pharma and itself an Indian API + CDMO player with global leadership in select APIs (anti-retroviral, oncology, cardiovascular, gastro). Closely comparable given KRKA Pharma inherits Laurus Labs' CDMO, regulatory, and API expertise for finished-dose development.
  • Krka, d. d., Novo mesto: Parent company of KRKA Pharma and one of Europe's largest generic pharmaceutical companies with €1.9B+ revenue and 18B+ tablets/capsules produced annually. Directly comparable business model (small-molecule generics for global markets) and shares product-development and manufacturing DNA with KRKA Pharma.

Others

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

KRKA Pharma compliance and trust

Trust signal

Compliance1 record

KRKA Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KRKA Pharma leadership team

Management profile

Number of profiles

Profiles1 record

KRKA Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KRKA Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KRKA Pharma

What does KRKA Pharma do?

KRKA Pharma develops and manufactures generic pharmaceutical products for India and global markets. The company is a 2024 joint venture between Krka Group (Slovenia) and Laurus Labs (India), currently constructing manufacturing and R&D facilities in Genome Valley, Hyderabad. Its core offering focuses on quality generic medicines, with capabilities inherited from parent companies spanning formulation development, API manufacturing, CDMO services, and large-scale production of tablets and capsules.

Is KRKA Pharma a public or private company?

KRKA Pharma is a private company. It is classified as corporate owned and is currently operating.

When was KRKA Pharma founded?

KRKA Pharma was founded in 2024.

Where is KRKA Pharma based?

KRKA Pharma is headquartered in Hyderabad, India, in the Asia region.

Who are KRKA Pharma's main competitors?

Broad incumbents on record are Lupin Limited, Sun Pharmaceutical Industries, Sandoz (Novartis), Cipla, Aurobindo Pharma, Dr. Reddy's Laboratories and Zydus Lifesciences (Cadila Healthcare). Direct peers are Laurus Labs and Krka, d. d., Novo mesto. Teva Pharmaceutical Industries is listed as an others.

Does KRKA Pharma have an API?

No public API is recorded for KRKA Pharma.

What industry is KRKA Pharma in?

KRKA Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals